Skip to main content
Stefano Tarantolo, MD, Oncology, Omaha, NE

StefanoRTarantoloMDFACP

Oncology Omaha, NE

Hematologic Oncology

Physician

Dr. Tarantolo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Tarantolo's full profile

Already have an account?

  • Office

    8303 Dodge St
    Suite 250
    Omaha, NE 68114
    Phone+1 402-354-8124
    Fax+1 402-354-5872

Education & Training

  • Rutgers Health/Robert Wood Johnson Medical School
    Rutgers Health/Robert Wood Johnson Medical SchoolFellowship, Hematology and Medical Oncology, 1988 - 1991
  • Jersey Shore University Medical Center
    Jersey Shore University Medical CenterResidency, Internal Medicine, 1985 - 1988
  • St. George's University School of Medicine
    St. George's University School of MedicineClass of 1985

Certifications & Licensure

  • NE State Medical License
    NE State Medical License 1992 - 2026
  • NJ State Medical License
    NJ State Medical License 1986 - 1993
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
  • Most Compassionate Doctor American Registry

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Ma...
    Stefano R. Tarantolo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

  • Curis Inc. (NASDAQ: CRIS) Doses First Subject in the Combination Therapy Study of CA-4948 in AML and MDS
    Curis Inc. (NASDAQ: CRIS) Doses First Subject in the Combination Therapy Study of CA-4948 in AML and MDSNovember 19th, 2021
  • Curis Inc. (NASDAQ: CRIS) Doses First Subject in the Combination Therapy Study of CA-4948 in AML and MDS
    Curis Inc. (NASDAQ: CRIS) Doses First Subject in the Combination Therapy Study of CA-4948 in AML and MDSNovember 19th, 2021
  • Finding Inner Peace Through Inner Beauty
    Finding Inner Peace Through Inner BeautyMay 21st, 2019
  • Join now to see all